Employees
66
Industry
Pharmaceutical Preparation Manufacturing
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.
Loading...
Open
3.45
Mkt cap
8.2M
Volume
109K
High
3.59
P/E Ratio
-0.28
52-wk high
18.80
Low
3.42
Div yield
N/A
52-wk low
3.42
Portfolio Pulse from Benzinga Newsdesk
December 15, 2023 | 7:02 am
Portfolio Pulse from Benzinga Insights
October 05, 2023 | 1:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 22, 2023 | 12:03 pm
Portfolio Pulse from Benzinga Insights
August 17, 2023 | 9:32 pm
Portfolio Pulse from Vandana Singh
July 18, 2023 | 1:26 pm
Portfolio Pulse from Benzinga Newsdesk
July 18, 2023 | 10:32 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.